1. Treatment adherence to the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab in six ODYSSEY phase 3 clinical studies with treatment duration of 52 – 104 weeks. (September 2016) Authors: Farnier, M.; Colhoun, H.M.; Sasiela, W.J.; Edelberg, J.; Asset, G.; Robinson, J.G. Journal: Atherosclerosis Issue: Volume 252(2016) Page Start: e254 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗